One US-made drug treats congenital syphilis, and the country is running short
The U.S. faces a shortage of Bicillin L-A, the only first-line injectable penicillin for treating syphilis in pregnant women to prevent congenital syphilis, due to a Pfizer recall linked to contamination. The FDA projects normal supply won’t return until December 2027, exacerbating rising congenital syphilis rates and disparities among Indigenous and Black infants.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Amid confusion over Pfizer’s emergency penicillin program, newborn is diagnosed with preventable syphilis
- STAT+: The shortage of many medicines in the U.S. remains a ‘systemic’ problem, a new analysis finds
- US is ‘simply choosing not to stop’ Ebola outbreak after massive public health cuts, experts say
- Gonorrhoea and syphilis hit record levels in Europe
- First malaria drug for babies is approved in ‘major public health milestone’